Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

It's no wonder people are attracted to dividend stock investments. Not only are the companies typically successful, profitable enterprises, but they usually have a long history of surviving various market cycles.

Dividend Stocks: Here's Where to Invest $1,000 Right Now

Nanobiotix SA

Shares of Nanobiotix SA NBTX, +1.57% shot up 52.1% toward a 17-month high in premarket trading Monday, after the France-based biotechnology company announced a global licensing and co-development agreement with Johnson & Johnson's JNJ, -1.45% Janssen Pharmaceutica NV for its cancer treatment. Under terms of the agreement, Nanobiotix will receive up to $60 million in cash near-term, including $30 million for licensing and up to $30 to help develop for NBTXR3, which is being evaluated for treatment of head and neck cancer.

Nanobiotix's stock soars after entering licensing, development deal with J&J's Janssen Pharmaceutica

Intuitive Surgical

Pfizer

Teladoc

Healthcare stocks stumbled in the first half as investors favored higher-growth industries. Investors piled into technology and consumer discretionary stocks.

Should You Buy the First Half's Worst-Performing Sector?

PepsiCo

Sysco

Dividends soften the blow from drawdowns in other positions, provide more than one way to reap a return from an investment, and allow maximum returns through dividend reinvestment.

Passive Income: 3 Dividend Kings Worth a Look

Walgreens

The great thing about strong, consistent dividend stocks? They tend to have strong, consistent businesses.

3 Beaten-Down Dividend Stocks Primed for a Profitable Comeback

Johnson & Johnson is one of today's biggest healthcare stocks by market value. The company has grown earnings and its dividend over time.

2 Reasons to Buy Johnson & Johnson, and 1 Reason to Sell

Duke Energy

Investors are always looking to buy the best defensive stocks. Investing in defense stocks provides stability during uncertain times due to their reliable government contracts.

The 3 Best Defensive Stocks to Buy Now (and Never Sell)

Johnson & Johnson's Supplemental Biologics Licensing Application of CARVYKTI was filed; approval would allow company to target a much earlier Multiple Myeloma patient population. Sales of CARVYTKI have not ramped up well since launch, but efforts are being made to increase manufacturing capacity to boost revenues. DARZALEX is another drug in the pipeline which has been approved to treat patients with Multiple Myeloma.

Johnson & Johnson: Supplemental BLA Of Carvykti Gives Great Growth Opportunity

Johnson & Johnson ( JNJ , Financial) is a leading company in the pharmaceutical and consumer health care industries that was founded in 1886. One of the most recognizable brands in the world with a well-established business, it is no hot growth stock that will explode overnight, but is instead a "boring" business that provides essential products and has proven its ability to grow profitably in the long run.

Johnson & Johnson: A Safe and Undervalued Dividend Aristocrat

Procter & Gamble

Verizon

In the ever-changing finance landscape, investors constantly hunt for dependable choices. Safe dividend stocks offer a strong option.

3 Super-Safe Dividend Stocks to Buy for the Rest of 2023

Merck

Johnson & Johnson and Merck both sell numerous popular medicines. Both also have encouraging pipelines that should lead to more products.

2 Best Biotech Stocks to Buy in July

Apple

Meta Data Ltd

Amazon

Microsoft

Visa

Think you missed your chance to profit on the S&P 500's most valuable stocks? Good news: analysts say there's still upside for most of them.

Seven Of The Top 10 Most-Valuable Stocks Are Still Cheap, Analysts Say

Bausch Health Companies Inc

Bausch + Lomb said on Thursday it has acquired Johnson & Johnson's eye and contact lens drops for $106.5 million in an all-cash deal to expand its portfolio of over-the-counter eye care products.

Bausch + Lomb buys J&J's dry eye relief drops for $107 mln

Chewy

It's important to consider your comfort level with risk before getting started. Plenty of exciting investment options exist today, whether you're a cautious or aggressive investor.

Where to Invest $1,000 Right Now

AbbVie

Bristol-Myers

AbbVie is a Dividend King with a high yield. Bristol Myers Squibb is an underrated bargain.

3 Spectacular Dividend Stocks to Buy in July

Alphabet

Lennar

Building long-term wealth requires patience. Instead of short-term trading, it requires finding companies that can compound for decades.

3 Long-Term Stocks to Make Your ‘Get Rich' Dreams Come True

Chevron

McDonald's

Since the second half of 2022, the economy has been volatile and this has led to many investors looking for safe and stable stocks to invest in. The market was in a rout and no industry has been spared but after all the uncertainty, we are finally looking at better days ahead.

3 Dividend Stocks to Buy Right This Minute

Lowe's

Altria

The article ranks 5 Dividend Kings, from highest to lowest quality. A Dividend King is any stock that has raised their dividend for 50+ consecutive years, making them the most consistent dividend payers in the market today. Being a dividend king usually coincides with lower dividend growth, but two of the stocks on today's list bucked that trend a bit.

Ranking These 5 Dividend Kings From Highest Quality To Lowest

Enterprise Products Partners

Mastercard

NextEra Energy

PennantPark Floating Rate Capital

Although the S&P 500 and Nasdaq Composite have bounced back in a big way in 2023, there's no guarantee the upward momentum has legs. Five rock-solid companies with well-defined competitive advantages stand out as exceptionally smart and safe buys for the second half of the year.

5 Genius Safe Stocks to Buy for the Second Half of 2023

Johnson & Johnson is strategically shifting towards high-growth sectors like pharmaceuticals and medical devices. Technical analysis of JNJ's stock price shows a strong bullish trend, indicating the potential for further growth. A robust bounce-back from the 50-month moving average affirms the investment potential for long-term shareholders.

Johnson & Johnson: Buy The Market (Technical Analysis)

Johnson & Johnson is a top-tier Sleep-Well-At-Night (SWAN) stock due to its consistent growth, strong cash flow, and regular returns to shareholders. The company's profile is strong, but its dividend yield is weak. We propose a trade that stands to generate far more income from this underlying company, for those whose top objectives are income and principal protection.

Johnson & Johnson: Pay Yourself 7% With This Bond-Like Exposure

Despite a top-shelf dividend and an elite innovation engine, J&J stock has lagged the broader markets since 2017. With a strong near-term outlook, J&J ought to deliver better results for shareholders in the years ahead.

Is Johnson & Johnson Stock a Strong Buy?

Johnson & Johnson's sales growth has not been impressive in recent years. If it can resolve its talc lawsuits, perhaps J&J can pursue more acquisitions.

Where Will Johnson & Johnson Be in 5 Years?

Amgen

Some of the biggest names in healthcare are on sale right now. J&J, AbbVie, Bristol Myers, Amgen, and Pfizer all trade at low valuations.

News for Johnson & Johnson Stock (JNJ)